GpIIb/IIIa

GpIIB / IIIa antagonist reagent

DISCONTINUED

INTENDED USE

Multiplate® is for research use only in the US and Canada.

Multiplate® GpIIb/IIIa-Antagonist is a reagent kit for use as quality control in research platelet aggregation studies on the Multiplate® analyzer. The GPIIb/IIIa antagonist blocks the GPIIb/IIIa receptor and leads to abolished aggregation in all Multiplate® tests.

GpIIb/IIIa antagonist inhibits the fibrinogen receptors of the platelets thus preventing their adhesion onto the sensor wires of the Multiplate® test cell. The reagent is employed in combination with the Multiplate® activating reagents TRAPtest, ASPItest, COLtest and ADPtest. Addition of GpIIb/IIIa antagonist to the blood sample leads to strongly reduced aggregation in TRAPtest, ADPtest, ASPItest and COLtest.

KIT COMPOSITION

Reagents, Storage and Stability

  • MP0280: Multiplate® GpIIb/IIIa antagonist, synthetic GpIIb/IIIa antagonist (molecular weight 495 g/mol in a concentration of 50 µg/ml), 3 x 0.5 ml, liquid, ready for use.
Unopened vials of the GpIIb/IIIa antagonist are stable until the expiry date printed on the vial label when stored stored at 2-8°C. Vials should be stored in an upright position. Stable 30 days after opening when stored at 2-8°C.

MEASUREMENT PRINCIPLE

GpIIb/IIIa antagonist contains a synthetic inhibitor of the platelet GpIIb/IIIa receptor with a molecular weight of 495 g/mol at a concentration of 50 µg/ml. Blocking the GpIIb/IIIa receptor leads to abolished aggregation in the Multiplate® tests. This allows the assessment of a positive control (strongly inhibited aggregation) in all tests. Furthermore unspecific effects of chemicals present in the sample onto the Multiplate® sensors can be elucidated (e.g. addition of oxidative substances into the blood).

Normally when the GpIIb/IIIa antagonist is added to the sample no significant impedance change during the analysis is recorded, because the binding of platelets onto the sensor wires is blocked. If a significant increase or decrease of impedance is still recorded when the GpIIb/IIIa antagonist is added to the sample, this suggests unspecific direct effects of substances in the blood or substances in reagents onto the sensor wires (e.g. oxidating effects).